Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-08-24 Director's Dealing
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-08-24 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Moleculin Biotech, Inc. It registers additional shares under the company's 2015 Stock Plan. The document includes details about the registration, incorporation by reference of prior filings, exhibits, and signatures. Form S-8 is specifically used for registering securities to be offered under employee benefit plans and is a capital market filing related to share issuance. It is not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2020-08-21 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2020, reporting the results of operations and financial condition for the quarter ended June 30, 2020. It specifically mentions that a press release announcing financial results is attached as Exhibit 99.1. The document itself is short (3048 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim or annual report.
2020-08-12 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-12 English
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K/A filing, which is an amendment to a previously filed Form 8-K. The content focuses on the corrected voting results from the company's 2020 Annual Meeting of Stockholders, including detailed vote counts for various proposals such as election of directors, ratification of auditors, reverse stock split authorization, increase in authorized shares under a stock plan, and adjournment authorization. The document explicitly states it is reporting the results of matters submitted to a vote at the Annual Meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting. The document is not the Annual Report, nor a proxy solicitation, nor a management report, but specifically a corrected voting results announcement. The length and detail confirm it is not a brief announcement but a full declaration of voting results.
2020-08-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce specific events or disclosures outside of regular periodic filings. The text indicates it is reporting a press release about new independent in vitro testing confirming antiviral activity of a compound. The document length is 3752 characters, which is relatively short and mainly contains the announcement and the press release as an exhibit. There are no financial statements or detailed financial data included. The document is not an Annual Report, Interim Report, Earnings Release, or any detailed financial or management report. It is a regulatory announcement of a material event. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-07-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.